Infectious Diseases | Pharma Marketer

Now, here’s something to think about: can angiogenesis inhibitors, the famous class of tumor-starving cancer drugs, actually make some kinds of cancer worse?

Posted in: In the Pipeline | 0 Comments »

Read the full story

Into the Clinic. And Right Back Out.

Wednesday, May 6th, 2009

Here’s a good example of why all of us in the industry tiptoe into Phase I trials, the first-in-man studies. A company called SGX, recently acquired by Eli Lilly, has been developing a kinase inhibitor (SGX523) targeting the enzyme cMET.

Posted in: In the Pipeline | 0 Comments »

Read the full story

Farewell to ACAT, and to Lots of Time and Money, Too

Tuesday, May 5th, 2009

Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had already been a drug target for some years before I first heard about it, and has remained one.

Posted in: In the Pipeline | 0 Comments »

Read the full story

Don’t Hit The Bunkers Just Yet

Monday, April 27th, 2009

Swine flu: is it time to panic yet? Actually, it never is, and this is a particularly useless time to start running in circles, despite the apparent non-stop coverage on the cable news channels.

Posted in: In the Pipeline | 0 Comments »

Read the full story